MARKET

ELDN

ELDN

Eledon Pharmaceuticals Inc
NASDAQ
2.630
-0.190
-6.74%
Opening 14:10 05/28 EDT
OPEN
2.780
PREV CLOSE
2.820
HIGH
2.826
LOW
2.520
VOLUME
146.70K
TURNOVER
0
52 WEEK HIGH
3.349
52 WEEK LOW
1.070
MARKET CAP
101.27M
P/E (TTM)
-1.8678
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ELDN last week (0520-0524)?
Weekly Report · 1d ago
Eledon Pharmaceuticals files to sell 21.1M shares for holders
Eledon Pharmaceuticals files to sell to sell shares for holders May 24, 2024 4:20 PM ETEledon pharmaceuticals, Inc. (ELDN) Stock. The company filed a prospectus related to a proposed resale of shares of its common stock by selling stockholders.
Seeking Alpha · 3d ago
ELEDON PHARMACEUTICALS INC: FILES FOR RESALE OF UP TO 21 MLN SHARES OF COMMON STOCK OFFERED BY SELLING STOCKHOLDERS- SEC FILING
Reuters · 3d ago
Weekly Report: what happened at ELDN last week (0513-0517)?
Weekly Report · 05/20 11:30
12 Health Care Stocks Moving In Friday's After-Market Session
Akso Health Group (NASDAQ:AHG) shares rose to $ during Friday's after-market session. The company's market cap stands at $ million. China SXT Pharmaceuticals shares increased by $ . Jaguar Health (Jaguar Health) shares declined by during the same session.
Benzinga · 05/17 20:31
LIDR, ELDN and IVP among pre-market losers
On the Move LIDR, ELDN and IVP among pre-market losers. Seritage Growth Properties (SRG) -28% after Q1 earnings release. AEye (LIDR) -14% announces 2024 annual general meeting of shareholders.
Seeking Alpha · 05/13 12:19
Weekly Report: what happened at ELDN last week (0506-0510)?
Weekly Report · 05/13 11:44
First human to receive transplanted pig kidney dies
First human to receive transplanted pig kidney dies. Rick Slayman, 62, of Massachusetts, received the transplant in March. The kidney was from a pig that had been genetically edited to remove genes harmful to a human recipient. Slayman had received a human kidney earlier this year.
Reuters · 05/12 18:17
More
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Webull offers Eledon Pharmaceuticals Inc stock information, including NASDAQ: ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.